Mayzent vs. Aubagio

Mayzent (siponimod) and Mayzent (teriflunomide) are used to treat relapsing forms of multiple sclerosis (MS). Mayzent and Mayzent belong to different drug classes. Mayzent is a sphingosine 1-phosphate receptor modulator and Mayzent is a pyrimidine synthesis inhibitor. Side effects of Mayzent and Mayzent that are similar include liver problems, nausea, and diarrhea. Side effects of Mayzent that are different from Mayzent include headache, high blood pressure (hypertension), falls, pain and swelling in extremities, dizziness, and slow heart rate. Side effects of Mayzent that are different from Mayzent include influenza, hair loss or thinning hair, burning or prickly feeling in your skin, and numbness or tingling in your hands or feet that is different from your MS symptoms. Mayzent may interact with “live” vaccines, cancer medications, immune-modulating drugs, immunosuppressive therapies, anti-arrhythmics, QT prolonging drugs, calcium channel blockers, other drugs that may decrease heart rate, beta-blockers, fluconazole, rifampin, carbamazepine, modafinil, and efavirenz. Mayzent may interact with ethinyl estradiol, levonorgestrel, and warfarin.

Common side effects of Mayzent include:

• headache,
• high blood pressure (hypertension),
• increased transaminase,
• falls,
• swelling of extremities,
• nausea,
• dizziness,
• diarrhea,
• slow heart rate, and
• pain in extremities

Common side effects of Aubagio include:

• liver problems,
• influenza,
• hair loss or thinning hair,
• nausea,
• diarrhea,
• burning or prickly feeling in your skin, or
• numbness or tingling in your hands or feet that is different from your MS symptoms.

Tell your doctor if you have serious side effects of Aubagio including:

• fever,
• chills,
• body aches,
• flu symptoms,
• sores in your mouth and throat,
• itching,
• tired feeling,
• loss of appetite,
• dark urine,
• clay-colored stools,
• yellowing of the skin or eyes,
• fast or racing heartbeats,
• confusion,
• little or no urinating,
• chest pain,
• dry cough,
• wheezing,
• feeling short of breath,
• skin redness or peeling,
• swelling,
• rapid weight gain, or
• severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.

Mayzent (siponimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Aubagio (teriflunomide) is a pyrimidine synthesis inhibitor used to treat relapsing forms of multiple sclerosis (MS).

Mayzent may interact with:

• "live" vaccines,
• cancer medications,
• immune-modulating drugs,
• immunosuppressive therapies,
• anti-arrhythmics,
• QT prolonging drugs,
• calcium channel blockers,
• other drugs that may decrease heart rate,
• beta-blockers,
• fluconazole,
• rifampin,
• carbamazepine,
• modafinil, or
• efavirenz.

Aubagio may increase exposure of ethinyl estradiol and levonorgestrel. Patients taking Coumadin (warfarin) should be closely monitored as interactions may occur. Aubagio may cause major birth defects if used during pregnancy. Pregnancy must be excluded before starting treatment with Aubagio. Pregnancy must be avoided while taking Aubagio treat relapsing forms of multiple sclerosis (MS). If Aubagio is used during pregnancy, or if the patient becomes pregnant while taking Aubagio, the drug should be discontinued immediately and an accelerated elimination procedure should be initiated. Consult your doctor before breastfeeding.

Initiate Mayzent with a 5-day titration. The recommended maintenance dosage of Mayzent is 2 mg.

The recommended dose for Aubagio is 7 mg or 14 mg taken orally, once daily, with or without food.